2021-2025 Kuwait Genetic Diseases, Cancer, Forensic, Paternity Molecular Diagnostics Market Opportunities-Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

Abstract

The report is available by section, market segment, and can be customized to your specific information needs and budget.

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products for diagnosing genetic diseases, cancer, as well as forensic and paternity/HLA testing during the next five years.

Report Presents

- Market shares of leading suppliers - Business and technological trends in major markets - Five-year test volume and sales forecasts - Feature comparison of major analyzers - Strategic profiles of leading market players and start-up firms developing innovative products - Specific product and business opportunities for instrument and consumable suppliers.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Market Segmentation Analysis

Market Segmentation Analysis

Five-year test volume and sales forecasts for major applications, including:

- Forensic Testing
- Cancer
- Paternity Testing/HLA Typing
- Genetic Diseases
- Others

Product/Technology Review

- Comparison of major molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and target/signal amplification methods.

- Worldwide listings of companies developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

- Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Cepheid/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Decode Genetics - Diadexus - Eiken Chemical - Elitech Group - Enzo Biochem - Exact Sciences - Fujirebio - Grifols - Hologic - Illumina - LabCorp - Leica Biosystems - Li-Cor Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Shimadzu - Siemens Healthineers - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher

Rationale

Genetic Diseases, Cancer, Forensic and Paternity testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Content
Table of Contents
I. Introduction
II. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
III. Design Criteria for Decentralized Testing Products
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. Worldwide Market and Technology Review
A. DNA Sequencing
1. Introduction
2. Sequencing Methods
3. Autoradiography
4. The Human Genome Project
5. Sequencing Automation
6. Image Scanners
7. Fluorescent Detection
8. Gene Profiling
9. Gene Expression
10. Polymorphism Screening
11. Protein Interaction Networks
B. DNA and RNA Probe Technologies
1. Basic Principles
2. Probe Preparation
3. The DNA Probe Test
4. Test Formats
5. Labeling Techniques
6. Amplification Methods
C. Detection Technologies
1. Radioactive Methods
2. Non-Isotopic Methods
D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche, Siemens Healthineers, and other suppliers.
E. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
- Liquid Transportation and Mixing
- Separation
- Reaction
- Detection
F. Pharmacogenomics
G. Major Applications
1. Cancer Testing
a. Overview
b. Major Cancer Types
- Prostate
- Lung
- Colon and Rectum
- Breast
- Skin
- Uterine
- Leukemia
- Oral
c. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
2. Genetic Diseases
a. Overview
b. Nucleic Acid Amplification
c. Chromosome Imaging
d. Genomics Technologies
e. Proteomics Technologies
f. Current Pharmacogenomic Tests
g. Future Pharmacogenomic Testing
h. Major Diseases
- Achondroplasia
- Autosomal Dominant Polycystic Kidney Disease
- Cancer
- Cosmetogenomics
- Cystic Fibrosis
- Down's Syndrome
- Duchenne and Becker Muscular Dystrophy
- Factor V (Leiden)
- Factor IX Deficiency
- Fragile X Syndrome
- Heart Disease
- Hemochomatosis
- Hemophilia
- Huntington's Disease
- Maternal-Fetal Incompatibility
- Multiple Endocrine Neoplasia
- Phenylketonuria (PKU)
- Polycystic Kidney Disease (PKD)
- Prenatal Screening
- Retinitis Pigmentosa
- Retinoblastoma
- Sickle Cell Anemia
- Spinal Muscular Atrophy
- Vitamin B12 Metabolism
i. Social Issues and Concerns
3. Forensic Testing
a. Overview
b. Multilocus and Single Locus Probes
c. DNA Profile Data Banks
d. Judicial Implementation
e. Major Crime Categories
f. Factors Contributing to the DNA Probe Market Expansion
- Technology Availability
- Use of Hair as Evidence
g. Wildlife Forensics
4. Paternity Testing/HLA Typing
5. Other Applications
a. Disease Susceptibility Testing
b. Cardiovascular Diseases
c. Diabetes
d. Alzheimer's Disease
e. Periodontal Disease
f. Plasma Purification
g. Organ Transplantation
h. Water Contamination
i. Other
H. Competing/Complementing
Technologies
1. Monoclonal Antibodies/Immunoassays
2. RNA Probes
3. Two-Dimensional Electrophoresis
4. Flow Cytometry
VII. Market Analyses: Molecular Diagnostic Analyzers and Reagent Market Shares and Forecasts for 100 Tests--Volume and Sales Forecasts
VIII. Competitive Assessments
The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad,Cepheid, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom,Leica Biosystems, Myriad Genetics, Ortho-Clinical Diagnostics, Qiagen, Quest Diagnostics, Quidel,Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher,Wako and others.
IX. Appendix: Major Universities and Research Centers Developing Innovative Molecular Diagnostic Technologies and Products